Apixaban (Eliquis-2.5/5) 30 Tablets
$109.00
Follow your healthcare provider’s recommendations regarding dosage adjustments, missed doses, and any other specific instructions related to your treatment regimen.
Description
Apixaban tablets, commonly marketed under the brand name Eliquis, are prescription medications used primarily for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and for the treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE).
Key Features:
- Anticoagulant Medication: Apixaban belongs to a class of drugs known as factor Xa inhibitors, which work by blocking the action of a key clotting factor in the blood, thereby reducing the risk of blood clots forming or worsening.
- Dual Indication: Eliquis tablets are indicated for both the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and the treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE).
- Prescription Medication: Eliquis tablets are available only with a prescription from a qualified healthcare provider and should be used under their supervision.
- Different Strengths: Eliquis tablets are available in various strengths, including 2.5 mg and 5 mg, allowing for individualized dosing based on the patient’s medical condition, risk factors, and other considerations.
Usage Instructions:
- Take Apixaban tablets exactly as prescribed by your healthcare provider, typically twice daily with or without food, unless otherwise instructed.
- Swallow the tablets whole with a full glass of water; do not crush, chew, or break them unless specifically advised by your doctor or pharmacist.
- Follow your healthcare provider’s recommendations regarding dosage adjustments, missed doses, and any other specific instructions related to your treatment regimen.
Additional information
| STRENGTHS | 2.5mg, 5mg |
|---|
Only logged in customers who have purchased this product may leave a review.
Reviews
There are no reviews yet.